Cardiovascular Risk FactorALTAIRNCT02087605
Automatic Image Analyzer to Assess Retinal Vessel Caliber
An observational study of Cardiovascular Risk Factor, run by Fundacion para la Investigacion y Formacion en Ciencias de la Salud at 1 site in Spain.
Trial summary
The objective of this work is the development and validation (reliability and validity) of the Automatic image analyzer to assess it retinal vessel caliber (ALTAIR) platform to analyze and validate its utility in different clinical settings. Read more about this study
- Who is it for?
- Ages 30 to 75 yearsHealthy volunteers can take part
- Conditions the study is for
- Cardiovascular Risk Factor
- How many people
- 400 participants
- Where
- 1 siteSpain
- Study dates
- Apr 2014to Jul 2016
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 to 75 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: 386 subjets of 30 to 75 years
Who may be able to join
- Some cardiovascular risk factor following the 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension
Who cannot join
- Psychological and / or cognitive impairment, no partners, educational and understanding limitations and severe comorbidity that would endanger his life in the next 12 months
Trial locations and contacts
1 site in 1 country.
Spain1 site
Primary care research unit La Alamedilla
Salamanca, Salamanca, 37003
About this study
Official title: Validation of the Automatic Image Analyzer to Assess Retinal Vessel Caliber (ALTAIR)
The objective of this work is the development and validation (reliability and validity) of the Automatic image analyzer to assess it retinal vessel caliber (ALTAIR) platform to analyze and validate its utility in different clinical settings.
Methods / Design Design : In the first phase , will be a cross- sectional study and a second phase will be a prospective observational study with annual follow-up for 4 years. The study will be conducted in primary care including 386 subjects. Main measurements: blood pressure, carotid intima-media thickness using carotid ultrasound , central blood pressure and wave velocity pulse by SphygmoCor system, Cardio-ankle vascular index (CAVI) by VASERA® VS1500 , evaluation of hypertrophy ventricular using a digital ECG and renal injury . Retinal vascular evaluation will be done by a non-mydriatic TOPCON TRCNW200 getting focused papilla, nasal and temporal and developed by software images automatically calculate the thickness of the retinal vessels , the arteriovenous index, the vascularized area and branching pattern . For validation software retina intra and inter - observer variability , the correlation of the tool measurement with AVindex , and concurrent validity with parameters of vascular structure and function and target organ damage and association analysis will analyze the different parameters of the estimated retina and evolution or appearance of new lesions in the target organs.
Discussion The validation of the tool contribute to the analysis of retinal vessels improved reliability by reducing the intervention of the observer and further validate the use of more information than the previously used , especially surface vascularization and vessel branching patterns .
Read the detailed description
Design and setting In the first phase, will be an observational descriptive study, with the primary objective of validating the instrument developed. Later, in a second phase will be a prospective observational study, with annual follow-up for 4 years. The study will be conducted in the field of primary care.
The study population will be subject 30 to 75 years with a cardiovascular risk factor defined by the European Hypertension Guide 2013 and does not meet any of the defined exclusion criteria: patients who can not comply with the requirements of the protocol due to mental and / or cognitive impairment, no partners, educational and understanding limitations and severe comorbidity that would endanger his life in the next 12 months. By consecutive sampling of all patients referred to the research unit for assessment of cardiovascular risk, their participation is requested from those who meet the inclusion criteria and have no reason for exclusion to the size of the estimated sample.
Sample size was estimated to detect a correlation coefficient between velocity and the pulse wave parameters retinal 0.15, alpha risk of 0.05 and a beta risk of 0.20, and an estimated loss by difficulty technical or abandonment of monitoring 10%, so 386 subjects, who will be included in the study required.
Software Validation retina For validation of the retina software Follow these steps after a previous training of evaluators who will make the evaluation of the images . 1 - intra- observer variability . Assessing the repeatability of the measurement, an operator must measure the same picture in the same individual, at least twice. To do this, an operator will evaluate 100 images of a random subsample of 50 patients with a gap of one week between the two embodiments . In this case , the operator and the images analyzed are the same on both days and will not have information on the previous assessment . 2 - inter-observer variability . To assess the reproducibility of the measurement system , a new operator, different from phase 1, evaluated the same 100 images previously analyzed . This operator will ignore the results that have been obtained in the previous phase. The two operators have the same experience in the field and in the use of software , in addition, both receive the same previous training. 3.- And with retina developed software program provides the results on the evaluation of arterial / venous , thickness of the vein and the artery index. To assess the degree of agreement between the two methodologies (AVindex ) valuation of 100 images were made with the two tools . In this way, we can show that the new method and provides the same results improves daily practice having more objective and faster processing of results. 4.- The validity of the measurement was analyzed in the total sample, 386 and 772 subjects fundus , analyzing the relationship of the results to the carotid intima-media thickness as a measure of vascular structure , the speed of the pulse wave as measure of vascular function and arterial stiffness gold standard (arterial stiffness ) in Cardio Ankle vascular Index , renal function , and electrocardiographic parameters estimated with the Framingham cardiovascular risk. 5.- also the association of the different parameters of the estimated retina and evolution or appearance of new lesions in target organs and cardiovascular monitoring of patients during the four years of the second phase of this project will be analyzed events
- Conditions
- Cardiovascular Risk Factor
- Keywords
- Vascular stiffness, retinal vessels, target organ damage
What is being measured
The primary outcome is the main question the study is designed to answer.
Thickness, surface and branching vessels of the retina
Thickness, surface and branching vessels of the retina evaluate by ALTAIR and AV index for two investigators
Measured: Up to eight mounths
Secondary outcomes (1)
Arterial stiffness
Assessment arterial stiffness by Cardio-ankle vascular index, Pulse Wave Velocity and Intima media thickness
Measured: Up to five years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Mar 2014 (estimated)
- Study startApr 2014
- Primary completionDec 2015
- Study completionJul 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Cardiovascular Risk FactorStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 400 participants (actual)
Sponsor and investigators
- Lead sponsor
- Fundacion para la Investigacion y Formacion en Ciencias de la Salud
- Sponsor type
- University, hospital or other
- Collaborators
- University of Salamanca
- Responsible party
- Sponsor
- Investigators
- Juan M Corchado, PhD, Study director, University of Salamanca
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02087605
- Sponsor's protocol ID
- C2013
- Acronym
- ALTAIR
- Status last verified
- Aug 2016
- First submitted
- 10 Mar 2014
- Last updated
- 1 Sep 2016
- Results posted
- No
- Data monitoring committee
- No
Publications
Garcia-Ortiz L, Recio-Rodriguez JI, Parra-Sanchez J, Gonzalez Elena LJ, Patino-Alonso MC, Agudo-Conde C, Rodriguez-Sanchez E, Gomez-Marcos MA; Vaso-risk group. A new tool to assess retinal vessel caliber. Reliability and validity of measures and their relationship with cardiovascular risk. J Hypertens. 2012 Apr;30(4):770-7. doi: 10.1097/HJH.0b013e3283506628.
PubMed 22306849Garcia-Ortiz L, Gomez-Marcos MA, Recio-Rodriguez JI, Maderuelo-Fernandez JA, Chamoso-Santos P, Rodriguez-Gonzalez S, de Paz-Santana JF, Merchan-Cifuentes MA, Corchado-Rodriguez JM; ALTAIR group. Validation of the automatic image analyser to assess retinal vessel calibre (ALTAIR): a prospective study protocol. BMJ Open. 2014 Dec 2;4(12):e006144. doi: 10.1136/bmjopen-2014-006144.
PubMed 25468505
Study at a glance
From the registry record, last updated by the sponsor on 1 Sep 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Validation of the Automatic Image Analyzer to Assess Retinal Vessel Caliber (ALTAIR)
- ClinicalTrials.gov ID
- NCT02087605
- Acronym / sponsor ID
- ALTAIR / C2013
- Conditions
- Cardiovascular Risk Factor
- Keywords
- Vascular stiffness, retinal vessels, target organ damage
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 400 participants (actual)
- Lead sponsor
- Fundacion para la Investigacion y Formacion en Ciencias de la SaludUniversity, hospital or other
- Collaborators
- University of Salamanca
- Study start
- Apr 2014
- Primary completion
- Dec 2015 (actual)
- Study completion
- Jul 2016 (actual)
- First posted
- 14 Mar 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of this work is the development and validation (reliability and validity) of the Automatic image analyzer to assess it retinal vessel caliber (ALTAIR) platform to analyze and validate its utility in different clinical settings.
Methods / Design Design : In the first phase , will be a cross- sectional study and a second phase will be a prospective observational study with annual follow-up for 4 years. The study will be conducted in primary care including 386 subjects. Main measurements: blood pressure, carotid intima-media thickness using carotid ultrasound , central blood pressure and wave velocity pulse by SphygmoCor system, Cardio-ankle vascular index (CAVI) by VASERA® VS1500 , evaluation of hypertrophy ventricular using a digital ECG and renal injury . Retinal vascular evaluation will be done by a non-mydriatic TOPCON TRCNW200 getting focused papilla, nasal and temporal and developed by software images automatically calculate the thickness of the retinal vessels , the arteriovenous index, the vascularized area and branching pattern . For validation software retina intra and inter - observer variability , the correlation of the tool measurement with AVindex , and concurrent validity with parameters of vascular structure and function and target organ damage and association analysis will analyze the different parameters of the estimated retina and evolution or appearance of new lesions in the target organs.
Discussion The validation of the tool contribute to the analysis of retinal vessels improved reliability by reducing the intervention of the observer and further validate the use of more information than the previously used , especially surface vascularization and vessel branching patterns .
Detailed description
Design and setting In the first phase, will be an observational descriptive study, with the primary objective of validating the instrument developed. Later, in a second phase will be a prospective observational study, with annual follow-up for 4 years. The study will be conducted in the field of primary care.
The study population will be subject 30 to 75 years with a cardiovascular risk factor defined by the European Hypertension Guide 2013 and does not meet any of the defined exclusion criteria: patients who can not comply with the requirements of the protocol due to mental and / or cognitive impairment, no partners, educational and understanding limitations and severe comorbidity that would endanger his life in the next 12 months. By consecutive sampling of all patients referred to the research unit for assessment of cardiovascular risk, their participation is requested from those who meet the inclusion criteria and have no reason for exclusion to the size of the estimated sample.
Sample size was estimated to detect a correlation coefficient between velocity and the pulse wave parameters retinal 0.15, alpha risk of 0.05 and a beta risk of 0.20, and an estimated loss by difficulty technical or abandonment of monitoring 10%, so 386 subjects, who will be included in the study required.
Software Validation retina For validation of the retina software Follow these steps after a previous training of evaluators who will make the evaluation of the images . 1 - intra- observer variability . Assessing the repeatability of the measurement, an operator must measure the same picture in the same individual, at least twice. To do this, an operator will evaluate 100 images of a random subsample of 50 patients with a gap of one week between the two embodiments . In this case , the operator and the images analyzed are the same on both days and will not have information on the previous assessment . 2 - inter-observer variability . To assess the reproducibility of the measurement system , a new operator, different from phase 1, evaluated the same 100 images previously analyzed . This operator will ignore the results that have been obtained in the previous phase. The two operators have the same experience in the field and in the use of software , in addition, both receive the same previous training. 3.- And with retina developed software program provides the results on the evaluation of arterial / venous , thickness of the vein and the artery index. To assess the degree of agreement between the two methodologies (AVindex ) valuation of 100 images were made with the two tools . In this way, we can show that the new method and provides the same results improves daily practice having more objective and faster processing of results. 4.- The validity of the measurement was analyzed in the total sample, 386 and 772 subjects fundus , analyzing the relationship of the results to the carotid intima-media thickness as a measure of vascular structure , the speed of the pulse wave as measure of vascular function and arterial stiffness gold standard (arterial stiffness ) in Cardio Ankle vascular Index , renal function , and electrocardiographic parameters estimated with the Framingham cardiovascular risk. 5.- also the association of the different parameters of the estimated retina and evolution or appearance of new lesions in target organs and cardiovascular monitoring of patients during the four years of the second phase of this project will be analyzed events
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 30 to 75 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- 386 subjets of 30 to 75 years
Key inclusion criteria (1 listed)
- Some cardiovascular risk factor following the 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension
Key exclusion criteria (1 listed)
- Psychological and / or cognitive impairment, no partners, educational and understanding limitations and severe comorbidity that would endanger his life in the next 12 months
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Thickness, surface and branching vessels of the retina
Time frame: Up to eight mounths
Thickness, surface and branching vessels of the retina evaluate by ALTAIR and AV index for two investigators
1 secondary outcome
Arterial stiffness
Time frame: Up to five years
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Sep 2016.
- Results publication: PubMed 22306849Garcia-Ortiz L, Recio-Rodriguez JI, Parra-Sanchez J, Gonzalez Elena LJ, Patino-Alonso MC, Agudo-Conde C, Rodriguez-Sanchez E, Gomez-Marcos MA; Vaso-risk group. A new tool to assess retinal vessel caliber. Reliability and validity of measures and their relationship with cardiovascular risk. J Hypertens. 2012 Apr;30(4):770-7. doi: 10.1097/HJH.0b013e3283506628.
- Derived from this study: PubMed 25468505Garcia-Ortiz L, Gomez-Marcos MA, Recio-Rodriguez JI, Maderuelo-Fernandez JA, Chamoso-Santos P, Rodriguez-Gonzalez S, de Paz-Santana JF, Merchan-Cifuentes MA, Corchado-Rodriguez JM; ALTAIR group. Validation of the automatic image analyser to assess retinal vessel calibre (ALTAIR): a prospective study protocol. BMJ Open. 2014 Dec 2;4(12):e006144. doi: 10.1136/bmjopen-2014-006144.
Related trials for Cardiovascular Risk Factor
Enrolling by invitationObservational study
Assessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0
Acute Kidney Injury, Fluid Overload
Not yet recruitingObservational study
Risk Factors for Spinal Cord Injury After Minimally Invasive Aortic Repair
Spinal Cord Ischemia
RecruitingObservational study
Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System
Metabolic Disease, Obesity
Enrolling by invitation
Nutrition in Rheumatoid Arthritis
Rheumatoid Arthritis (RA)
Active, not recruitingObservational study
Predicting Diabetic Retinopathy From Risk Factor Data and Digital Retinal Images
Diabetic Retinopathy, Diabetic Macular Edema
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Juan M Corchado, PhD study director
University of Salamanca
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cardiovascular Risk Factor, run by Fundacion para la Investigacion y Formacion en Ciencias de la Salud at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 1 Sep 2016. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Thickness, surface and branching vessels of the retina (time frame: Up to eight mounths). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02087605, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Sep 2016.